EGFR-Mutant Non-Small Cell Lung Cancer research hub

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of BG-60366 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

This early-stage study is looking at a new medicine for people with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. Researchers want to see if the medicine is safe, what doses people can handle, and how it works in the body and against cancer.